Welcome to our dedicated page for Cardinal Health news (Ticker: CAH), a resource for investors and traders seeking the latest updates and insights on Cardinal Health stock.
Cardinal Health, Inc. distributes pharmaceuticals and specialty products and manufactures and distributes medical, laboratory, home-health and direct-to-patient products and services. The company also operates nuclear pharmacies and manufacturing facilities and provides performance and data solutions for healthcare customers.
Recurring company updates cover financial results and fiscal outlooks, dividend actions, share repurchases, debt activity, segment performance in Global Medical Products and Distribution, at-Home Solutions, Nuclear and Precision Health Solutions and OptiFreight Logistics. Other developments include biosimilars and advanced-therapy research reports, Actinium-225 production capacity for radiopharmaceutical applications, and board governance changes.
Cardinal Health (NYSE: CAH) announced definitive agreements to acquire AdaptHealth's Diabetes Health business and all of Strive Medical for a combined purchase price of approximately $360 million in cash, subject to working capital adjustments. The deals support Cardinal Health's at-Home Solutions growth strategy in diabetes management and urology.
According to Cardinal Health, AdaptHealth's Diabetes Health business serves more than 225,000 people annually via a centralized mail-order, direct-to-patient model, while Strive Medical serves more than 20,000 people annually in urology, wound care, ostomy and incontinence. Building on the earlier Advanced Diabetes Supply acquisition, Cardinal Health reports it has migrated all ADS volume to its at-Home Solutions network, onboarded nearly 500,000 new customers, and launched the ContinuCare Pathway digital referral program. The new transactions are subject to customary closing conditions, including regulatory approvals, and are expected to be accretive to non-GAAP EPS within 12 months after closing.
Cardiovascular Logistics (CVL), a national cardiology management services organization, appointed Gary M. Kirsh, M.D. as Chief Executive Officer, effective immediately. Dr. Kirsh has served on CVL's board since November 2025 and has over three decades of experience building physician-led specialty platforms.
Dr. Kirsh co-founded and formerly led Solaris Health, which he expanded to 1,000 providers across 250+ locations in 14 states before its approximately $2.4 billion acquisition by Cardinal Health (NYSE: CAH) in November 2025, where it became part of The Specialty Alliance and the cornerstone of a national Urology Alliance. CVL founder and outgoing CEO David Konur transitions to Chairman of the Board, focusing on strategy, key relationships, and acquisitions alongside partner Lee Equity Partners. According to CVL, the platform now includes over 425 providers across seven states, supporting leading cardiovascular practices while emphasizing independent, physician-led care.
Cardinal Health (NYSE: CAH) will release its fourth-quarter and full-year fiscal 2026 financial results on August 11, 2026, before NYSE trading opens.
A results discussion will be webcast at 8:30 a.m. Eastern, with slides and a replay available on the Investor Relations page for 12 months.
Cardinal Health (NYSE: CAH) said its Board approved a quarterly dividend increase to $0.5158 per share, to be paid from the company’s capital surplus. The dividend is payable on July 15, 2026 to shareholders of record at the close of business on July 1, 2026.
Cardinal Health (NYSE: CAH) reported Q3 FY26 revenue of $60.9 billion, up 11% year-over-year. GAAP operating earnings fell to $509 million (–30%) and GAAP diluted EPS to $1.69 (–20%) after a $184 million goodwill impairment. Non-GAAP operating earnings rose to $956 million and non-GAAP diluted EPS to $3.17. The company raised FY26 non-GAAP EPS guidance to $10.70–$10.80, narrowed adjusted free cash flow to $3.3–$3.7 billion, reduced debt, and completed year-to-date buybacks of $1.0 billion.
Cardinal Health (NYSE: CAH) released its 2026 Advanced Therapies Report: Perspectives on Community Expansion, reporting provider momentum to move gene-, cell- and tissue-based treatments into outpatient and community settings to improve access and patient experience.
The report surveyed >160 clinicians and administrators, notes 61 approved advanced therapies in the U.S. today and projects that total will nearly triple by 2030, while highlighting infrastructure, staffing and partnership needs for safe community delivery.
Cardinal Health (NYSE:CAH) announced on April 1, 2026 an expansion of Actinium-225 (Ac-225) production at its Center for Theranostics Advancement in Indianapolis. The company added a high-capacity production line to its DMF, quadrupled weekly output since late 2024, and plans further capacity increases in 2026 to support clinical and future commercial targeted alpha therapies.
The expanded supply has supported more than 15 clinical trials and aims to improve access for developers of therapies for prostate, neuroendocrine, breast, colon, melanoma, and lymphoma.
Cardinal Health (NYSE: CAH) will release third-quarter fiscal 2026 results on April 30, 2026 before the New York Stock Exchange opens. A webcast discussion begins at 8:30 a.m. Eastern. Slides and a replay will be available on the company Investor Relations page for 12 months; no access code is required.
Cardinal Health (NYSE: CAH) appointed Patricia A. Hemingway Hall as Chair of the Board, effective March 23, 2026, succeeding Gregory B. Kenny upon his retirement. Ms. Hemingway Hall has served on the board since 2013 and chaired the Governance and Sustainability Committee for nearly seven years.
The company said Ms. Hemingway Hall brings deep healthcare leadership as former CEO of Health Care Service Corporation. Cardinal Health reiterated confidence in its fiscal 2026 outlook and will release third quarter fiscal 2026 earnings on April 30.
Cardinal Health (NYSE: CAH) released its 2026 Biosimilars Report highlighting measured cost savings and high provider confidence in biosimilars across physician practices. The report cites $56 billion in U.S. savings since 2015 and projects up to $181 billion in future savings if market and policy conditions align.
Key metrics: 99% of surveyed providers feel comfortable explaining biosimilars, oncology biosimilars reach an average 81% market share within five years, and nearly 25 biosimilars are expected to receive FDA approval over the next two years.